Prevention of Bone Metastases in Patients with High-risk Nonmetastatic Prostate Cancer Treated with Zoledronic Acid: Efficacy and Safety Results of the Zometa European Study (ZEUS)-Reference-Cited by-同舟云学术

Prevention of Bone Metastases in Patients with High-risk Nonmetastatic Prostate Cancer Treated with Zoledronic Acid: Efficacy and Safety Results of the Zometa European Study (ZEUS)

Published:2015-03 Issue:3 Volume:67 Page:482-491
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Wirth Manfred,Tammela Teuvo,Cicalese Virgilio,Gomez Veiga Francisco,Delaere Karl,Miller Kurt,Tubaro Andrea,Schulze Matthias,Debruyne Frans,Huland Hartwig,Patel Anup,Lecouvet Frederic,Caris Christien,Witjes Wim

Publisher

Elsevier BV

Subject

Urology

Reference24 articles.

1. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma;Carlin;Cancer,2000

2. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up;Studer;Eur Urol,2014

3. A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma;Serpa Neto;BMC Urol,2010

4. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma;Saad;J Natl Cancer Inst,2002

5. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer;Smith;N Engl J Med,2001

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The emerging role of osteoclasts in the treatment of bone metastases: rationale and recent clinical evidence;Frontiers in Oncology;2024-08-01

2. A multifaceted role of bisphosphonates from palliative care to anti-cancer therapy in solid tumors;Journal of Oncology Pharmacy Practice;2024-07-26

3. Enhancing the anticancer effect of androgen deprivation therapy by monocarboxylate transporter 1 inhibitor in prostate cancer cells;The Prostate;2024-04

4. Novel Therapeutic Targets on the Horizon: An Analysis of Clinical Trials on Therapies for Bone Metastasis in Prostate Cancer;Cancers;2024-01-31

5. FOXA1-dependent PUS1 regulates EIF3b stability in a non-enzymatic pathway mediating prostate cancer bone metastasis;International Journal of Biological Sciences;2024